We’re excited to announce that HD Reach is adopting an Office-Without-Walls format that allows our team to work with you on your HD journey.
Read about how one researcher at Duke is working to advance our understanding of treatments for Huntington’s Disease while dealing with the inconveniences of Covid-19.
Dr. Robert Trestman, a nationally recognized expert in psychiatry and population health who is a Professor and Chair of the Department of Psychiatry and Behavior Medicine at Virginia Tech and the Carilion Clinic provides some great advice on how to battle anxiety during the Coronavirus crisis. Dr. Trestman will be a featured speaker at the HD Reach Educational Conference.
One a very private person, the other an extremely public person. Both have Huntington’s Disease.
There are many sad stories related to HD and this is one of them. If this topic stirs up conversations or emotions, please remember that we are always here for you.
There’s a 50% probability Danielle could inherit the disease her mum has. After taking a test, she’s about to find out. Would you want to know?
The ability to predict HD onset is getting closer. Read more about current research
For the entire month of February, City Kitchen Chapel Hill will donate $5 from each Giveback Community Cocktail sold! Have a cocktail while supporting all of the families that rely on HD Reach to be a source of information, compassion and care.
New research from Duke University has found new roles for Huntington’s Protein. Read here if you want to learn how this piece of information may inform future treatments for HD.
HD Buzz has filtered out some of the noise about the Wave huntingtin-lowering trial announcement and explained how real progress is being accomplished in the effort to find safe and effective treatments for Huntington’s Disease.
Take this quiz.
New research raises questions about how early the mutant HD gene is impairing the brain’s development.
If you’re interested in research for treatment of HD and/or worms, you may want to read this article.
HSG announced the initiation of KINECT-HD, a Phase III clinical study of valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of chorea associated with HD.